ロード中...
Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20(+)and 70% for CD20(−) (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for...
保存先:
| 出版年: | Leuk Res Rep |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8076710/ https://ncbi.nlm.nih.gov/pubmed/33936943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2021.100240 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|